ClinicalTrials.gg
WithdrawnNCT04469062LUCENT-ACTUpdated May 6, 2021

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

A Phase 3 interventional study of Mirikizumab IV and Mirikizumab SC in Ulcerative Colitis, sponsored by Eli Lilly and Company. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-06.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was withdrawn
The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.

Enrollment
13th of 13
0 · median 172
Started
2021
with 1 other
Phase 3
7 of 13
1 open now
Registered
6th of 13
by date
Lead sponsor
9 of 13
Eli Lilly and Company

Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 13th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 3, and was the 6th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mirikizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Interleukin-23 (IL-23) antibody
  • IL-23p19
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a diagnosis of UC for at least 3 months prior to baseline
  • Participants must have a confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS)
  • Participants must have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic therapy for UC
  • Participants must, if female, meet the requirements

Exclusion criteria

Exclusion Criteria:

  • Participants must not have a current diagnosis of Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis)
  • Participants must not have had a previous colectomy
  • Participants must not have current evidence of toxic megacolon
  • Participants must not have prior exposure to anti-IL-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab), vedolizumab, or natalizumab
  • Participants must not have prior clinical failure or intolerance to anti-IL12p40 antibodies (e.g. ustekinumab), anti-integrin antibodies other than vedolizumab and natalizumab (e.g. etrolizumab) or anti-integrin ligand antibodies (e.g. ontamalimab) within 4 weeks prior to screening endoscopy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Mirikizumab

    Mirikizumab administered intravenously (IV) and subcutaneously (SC).

    Drug: Mirikizumab IV · Drug: Mirikizumab SC

  • Active comparator
    Vedolizumab

    Vedolizumab administered IV.

    Drug: Vedolizumab IV

  • Placebo comparator
    Placebo

    Placebo administered SC and IV.

    Drug: Placebo IV · Drug: Placebo SC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Histologic Remission

    Histologic remission based on histology.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants in Symptomatic Remission

    Symptomatic remission based on modified Mayo Score (MMS) stool frequency (SF) and rectal bleeding (RB) subscores.

    Time frame: Week 52

  2. Percentage of Participants in Clinical Remission

    Clinical remission based on MMS.

    Time frame: Week 52

  3. Percentage of Participants in Endoscopic Remission

    Endoscopic remission based on MMS ES.

    Time frame: Week 52

  4. Percentage of Participants with Clinical Response

    Clinical response based on MMS.

    Time frame: Week 12

  5. Percentage of Participants with Corticosteroid (CS) Free Remission without Surgery (Subgroup of Participants on CS at Baseline)

    CS free remission without surgery based on clinical remission, symptomatic remission and no CS use.

    Time frame: Week 52

  6. Percentage of Participants with Resolution of Extraintestinal Manifestations (EIMs) Among Those That had Them at Baseline

    Percentage of participants with resolution of EIMs among those that had them at baseline.

    Time frame: Week 52

  7. Change from Baseline on the Inflammatory Bowel Disease Questionnaire (IBDQ) Score

    Change from baseline on the IBDQ score.

    Time frame: Baseline, Week 52

  8. Percentage of Participants Undergoing Surgery for UC (Including Colectomy)

    Percentage of participants undergoing surgery for UC (including colectomy).

    Time frame: Week 52

  9. Percentage of Participants Hospitalized for UC

    Percentage of participants hospitalized for UC.

    Time frame: Week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2021; primary completion for Mar 2024, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2020
First posted
Jul 13, 2020
StartEst.
Apr 20, 2021
Primary completionEst.
Mar 13, 2024
CompletionEst.
Jun 5, 2024
Last update
May 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04469062
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Apr 20, 2021 (estimated)
Primary completion
Mar 13, 2024 (estimated)
Completion
Jun 5, 2024 (estimated)
Last update
May 6, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion